Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07079657

Thulium Laser and Growth Factors for Androgenetic Alopecia

Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and emotional impact on those affected.

Various therapies are currently approved for the treatment of AGA in men and women, including topical minoxidil, topical or systemic finasteride, platelet-rich plasma and hair transplantation. In addition to these pharmacological and surgical interventions, laser therapies including thulium laser with growth factors have gained popularity.

Despite the clinical use of the thulium laser with growth factors in combination with LED phototherapy, there are only a few studies to date that have adequately investigated the objective and patient-side benefits of this therapy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Androgenetic Alopecia (AGA) Alopecia Hair Diseases Hypotrichosis Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Medical Center Hamburg-Eppendorf

Hamburg, Free and Hanseatic City of Hamburg, 20246, Germany

Location status: Recruiting

Location contact

Lynhda Nguyen, Dr. med.

CONTACT

[email protected]

+49 (0)40 7410 54289

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women aged 18 and over
  • Good general health, no relevant previous illnesses
  • Presence of an AGA
  • Cognitive ability and willingness to give consent (informed consent)
  • Be willing and able to attend follow-up visits

Exclusion criteria

  • Age < 18 years
  • Pregnant or breastfeeding women
  • Scarring alopecia, alopecia due to dermatoses (e.g. lichen ruber, lupus erythemodes,...), alopecia due to chemical or physical noxae, and other non-AGAs
  • Significant scarring of the region to be treated
  • Significant open wounds or lesions in the region to be treated
  • Metallic implants in the head region
  • Mental illnesses (psychoses, body perception disorders)
  • Use of isotretinoin or other retinoids, psychotropic drugs, coumarins or heparins in the last 2 weeks
  • Resurfacing (fractional, ablative, non-ablative) of the affected region < 2 months before and during the study period
  • Tendency to excessive scarring
  • Lack of informed consent and/or data protection declarations

Treatment and study plan

Thulium laser + growth factor serum + LED

Procedure

3 sessions at intervals of 6 weeks

Thulium laser + growth factor serum

Procedure

3 sessions at intervals of 6 weeks

Thulium Laser

Procedure

3 sessions at intervals of 6 weeks

Primary outcomes

  1. Subject Global Aesthetic Improvement Scale

    Time frame: 1 and 6 months post-treatment

    scale from 0 (very much improved) to 4 (worse)

  2. Hair density

    Time frame: at baseline, and 1 and 6 months post-treatment

    measurement of hair density before and after treatment

  3. hair thickness

    Time frame: at baseline, and 1 and 6 months post-treatment

    hair thickness before and after treatment

Secondary outcomes

  1. pain intensity

    Time frame: Periprocedural

    pain intensity during treatment using a numeric rating scale from 0 (no pain) to 10 (unbearable pain)

Study contacts

Contact information is provided by the study sponsor or research team.

Lynhda Nguyen, Dr. med.

CONTACT

[email protected]

+49 (0)40 7410 54289

Sponsors and collaborators

Lead sponsor

Universitätsklinikum Hamburg-Eppendorf

Other

Registry information

Official study title

Thulium Laser and Growth Factors for Androgenetic Alopecia - a Prospective, Clinical Study

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jul 23, 2025
Registry last updated
Jul 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.